絞り込み

17057

広告

Health-related quality of life in patients with fully resected BRAF mutation-positive melanoma receiving adjuvant vemurafenib.

著者 Schadendorf D , Di Giacomo AM , Demidov L , Merelli B , Bondarenko I , Ascierto PA , Herbert C , Mackiewicz A , Rutkowski P , Guminski A , Goodman GR , Simmons B , Ye C , Hong A , Lewis K ,
Eur J Cancer.2019 Nov 05 ; 123():155-161.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)

Full Text Sources

Miscellaneous

The aim of the study was to assess the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC-IIIC melanoma.
PMID: 31704549 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード